Related Experiment Video
Updated: Jul 9, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Dynamic contrast enhanced MRI of mouse fibrosarcoma using small-molecular and novel macromolecular contrast agents
Teodora Ivanusa1, Katarina Beravs, Jure Medic
1Veterinary Faculty, University of Ljubljana, Slovenia.
Abstract:
The aim of the study was a comparison of 2 novel macromolecular contrast agents, Gadomer-17 and Polylysine-Gd-DTPA, with commercially available Gd-DTPA in determining the quality of tumor microvasculature by dynamic contrast enhanced MRI. Three groups of 5 mice with SA-1 tumors were studied. To each group of animals one contrast agent was administered; i.e. the first group got Gd-DTPA, the second group Gadomer-17 and the third group Polylysine-Gd-DTPA. To perform dynamic contrast enhanced MRI a standard keyhole approach was used by which consecutive signal intensity change due to contrast agent accumulation in the tumor was measured. From the obtained data, tissue permeability surface area product PS and fractional blood volume BV were calculated on a pixel-by-pixel basis. PS and BV values were calculated for each contrast agent. Based on the values, contrast agents were classified according to their performance in characterizing tumor microvasculature. Results of our study suggest that Gadomer-17 and Polylysine-Gd-DTPA are significantly superior to Gd-DTPA in characterizing tumor microvasculature.
Insights
Two novel contrast agents, Gadomer-17 and Polylysine-Gd-DTPA, significantly outperformed Gd-DTPA in assessing tumor microvasculature quality using dynamic contrast-enhanced MRI.
Area of Science:
- Biomedical Imaging
- Oncology
- Radiology
Background:
- Assessing tumor microvasculature is crucial for cancer diagnosis and treatment.
- Dynamic contrast-enhanced MRI (DCE-MRI) is a key technique for this evaluation.
- Novel macromolecular contrast agents offer potential improvements over existing agents.
Purpose of the Study:
- To compare the efficacy of Gadomer-17 and Polylysine-Gd-DTPA against Gd-DTPA.
- To determine the quality of tumor microvasculature using these contrast agents.
- To evaluate their performance in dynamic contrast-enhanced MRI.
Main Methods:
- A comparative study involving three groups of mice with SA-1 tumors.
- Administration of Gd-DTPA, Gadomer-17, or Polylysine-Gd-DTPA to separate groups.
- Dynamic contrast-enhanced MRI using a standard keyhole approach.
- Calculation of tissue permeability surface area product (PS) and fractional blood volume (BV) on a pixel-by-pixel basis.
Main Results:
- Gadomer-17 and Polylysine-Gd-DTPA demonstrated significantly superior performance compared to Gd-DTPA.
- The agents were classified based on their ability to characterize tumor microvasculature.
- PS and BV values varied between the contrast agents, indicating differential characterization capabilities.
Conclusions:
- Gadomer-17 and Polylysine-Gd-DTPA are more effective than Gd-DTPA for characterizing tumor microvasculature.
- These novel agents show promise for improving DCE-MRI in oncology.
- Further research may validate their clinical utility in cancer imaging.
